Can a new injection help tackle obesity? a safety trial begins

NCT ID NCT07765160

Not yet recruiting Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing an investigational drug called IBI3040, given as an injection under the skin. The study will first give a single dose to healthy adults to check safety, then multiple doses to overweight or obese adults to see how the drug behaves and whether it is well-tolerated. The main goal is to assess side effects and how the body processes the drug, not yet to measure weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3040, an investigational drug given by injection under the skin
What this could lead to: If successful, this could lead to a new treatment option for overweight or obesity, potentially helping with weight management.
What could go wrong: This is an early-phase trial focused on safety, so it's unknown if the drug will be effective. Possible side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANTS OVERWEIGHT OR OBESE PARTICIPANTS

Contacts and locations

Locations

Huashan Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, 201107, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.